Contact
QR code for the current URL

Press release Box-ID: 364055

GLYCOTOPE GmbH Robert-Roessle-Str. 10 13125 Berlin, Germany http://www.glycotope.com
Contact Mr Dr. Franzpeter Bracht +49 30 94892600
Company logo of GLYCOTOPE GmbH
GLYCOTOPE GmbH

Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX(TM) and Enrolls First Patients in Clinical Trial

(PresseBox) (Berlin, Germany, )
Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope's next generation antibody CetuGEX(TM) (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

"For Glycotope, the approval of CetuGEX(TM) , our second antibody in the clinic, represents another important milestone," says Steffen Goletz, CEO & CSO of Glycotope. "CetuGEX(TM) is our first in a series of next generation biotherapeutic products. We expect that the strong advantages in various product aspects we have seen in preclinical studies will manifest in a clear clinical superiority compared to the currently marketed product. In addition, the second cell line of Glycotope's glycooptimization platform GlycoExpress(TM) based on human cell lines has now been approved, meeting our ambitions for quality and speed." CetuGEX(TM) was the second antibody in clinical stage produced in Glycotope's own GMP facility in Heidelberg.

About CetuGEX(TM)

CetuGEX(TM) is an improved version of a currently marketed anti-EGFR antibody which has been approved for the treatment of colorectal and head & neck cancers. The antibody's fully human glycosylation is optimized to yield a largely improved antitumor ADCC activity, bioavailability and contains no nonhuman immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. This was achieved with Glycotope's proprietary technology platform GlycoExpress(TM) , a screening and high yield production system of glycoengineered human cell lines.

GLYCOTOPE GmbH

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant carbohydrate structures known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress(TM) , one of the company's proprietary technologies, allows making existing and new biopharmaceutical drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all steps from lead discovery, preclinical development, GMP production and clinical development. Glycotope's most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX(TM) ) and significantly improved versions of antibodies as well as other marketed therapeutic proteins.

www.glycotope.com

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.